Search
Close this search box.

A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

The aim of the trial is to assess the benefit of adding high precision radiation therapy to chemotherapy and surgery for the treatment of pancreatic cancer.

Primary Sponsor

Australasian Gastro-Intestinal Trials Group (AGITG)

Collaborating Groups

Trans Tasman Radiation Oncology Group (TROG) and NHMRC CTC

Accrual Target

120

Expected Date of Accrual

31 December 2024

Trial Chairperson

Dr Andrew Oar, Gold Coast University Hospital

Trial Contact

MASTERPLAN.study@sydney.edu.au

Clinical Trial Registration

Related Post

5 December, 2024

Extended follow-up of TROG 99.03 lymphoma trial published

5 December 2024: Study shows huge improvement in progression-free

28 November, 2024

Meet TROG President: A/Prof Puma Sandaresan

28 November 2024: In this Q&A, TROG President A/Prof